@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix mgi: . @prefix proteinModification: . @prefix psimod: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:variantOf mgi:1861437; a proteinModification:, psimod:00696 . sub:_2 occursIn: species:10090; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject schem:SU%2011274; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:\"SU 11274\") -| p(MGI:Gsk3b,pmod(P,S,9))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "1.4" . sub:_3 prov:value "We found that the dosedependent reduction in tyrosine phosphorylation of cellular proteins after SU11274 treatment correlated with reduced serine phosphorylation of AKT (Ser308, Ser473) as well as its targets GSK-3 (Ser21/9) and the proapoptotic transcription factor FKHR (Ser256; Fig. 4B)."; prov:wasQuotedFrom pubmed:14500382 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:14500382; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:16.885+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }